In contrast to other commonly used biomarkers such as cardiac troponins and N-terminal proB-type natriuretic peptide (NT-proBNP), secretoneurin (SN) is associated with biological processes linked to heart cell calcium, a key mechanism in the regulation of heart rhythm and has been described as the “missing link biomarker” in cardiovascular disease risk assessment1. This unique biological function may explain why SN has been shown to be an independent and strong predictor of mortality in all major patient cohorts tested, including patients with ventricular arrhythmia, acute heart failure, and acute respiratory failure patients with CVD and severe sepsis2,3,4,5. CardiNor has a comprehensive clinical program to further strengthen and widen the clinical documentation.
IBL-America now provides the CardiNor Secretoneurin ELISA test for research use only in the US.
Available Now: HUMAN SECRETONEURIN ELISA
Informational Pamphlet: Will Secretoneurin Be The Next Big Thing?
- 1.Mark E. Anderson, Editorial: Will Secretoneurin Be the Next Big Thing? J Am Coll Cardiol 2015,65
- 2.Ottesen et.al, Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol 2015 Feb 3;65(4):339-351
- 3.Røsjø et.al, on behalf of the FINNSEPSIS and FINNALI Study Groups. Prognostic Value of Secretoneurin in Critically Ill Patients With Infections. Crit Care Med 2016 Oct;44(10):1882-90
- 4.Myhre et.al, Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure: Data from the FINNALI Study. Clin Chem 2016 Oct;62(10):1380-89
- 5.Røsjø et al, for the ALBIOS Biomarkers Study Investigators. Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study. Crit Care Med 2018.
Data from the GISSI Heart Failure study where 1273 patients followed for more than 6 years had their Secretoneurin measured, is presented as Moderated ePosters at the ESC Congress in Barcelona August 28th, station 3 at 14:15 by Dr. Helge Røsjø MD, PhD (Akershus University Hospital, Norway): Circulating Secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure.